Introduction

Histamine was one of the earliest mediators of allergic responses to be identified, with its role in modulating allergy first recognized in 1932. Since this initial discovery, extensive research has established histamine as a multifunctional biogenic amine involved not only in allergic inflammation but also in a broad range of physiological and pathological processes, including autoimmune regulation, gastric acid secretion, hematopoiesis, and neurotransmission.[1] Histamine is ubiquitously distributed throughout the body; however, it is stored in particularly high concentrations within the secretory granules of mast cells, especially in the lung parenchyma and airway mucosa, as well as in circulating basophils, where it is released upon immune activation. Histamine is a potent vasoactive molecule that exerts diverse effects on bronchial smooth muscle, vascular endothelium, and nociceptive sensory nerves, thereby contributing to bronchoconstriction, increased vascular permeability, and pruritus, respectively.[2] Through these actions, histamine plays a central role in orchestrating acute and chronic inflammatory responses. Beyond its classical role in immediate hypersensitivity reactions, histamine is now also recognized as an essential immunomodulator that influences both innate and adaptive immune responses by regulating cytokine production, immune cell differentiation, and leukocyte recruitment.[1] The expanding understanding of histamine's pleiotropic effects has led to the identification of multiple histamine receptor subtypes (H1-H4), each mediating distinct biological functions. These discoveries have significantly advanced our understanding of histamine's involvement in the pathophysiology of inflammatory and immune-mediated diseases, including asthma, autoimmune disorders, and chronic inflammatory conditions. As a result, histamine signaling has emerged as an important therapeutic target, with ongoing research aimed at developing more selective receptor antagonists and modulators to improve treatment efficacy and minimize adverse effects.[3]

Fundamentals

Histamine is a biogenic amine synthesized from the amino acid L-histidine exclusively by the enzyme L-histidine decarboxylase (HDC), which requires pyridoxal-5′-phosphate as an essential cofactor.[4] HDC is widely expressed in multiple cell types throughout the body, including gastric mucosal cells, neurons, gastric parietal cells, mast cells, and basophils, enabling histamine production in diverse physiological contexts.

Among histamine-producing cells, mast cells and basophils are unique in their ability to synthesize, store, and release large quantities of histamine. In these cells, histamine is stored in cytoplasmic granules in association with negatively charged proteoglycans (primarily heparin in mast cells and chondroitin-4-sulfate in basophils), which facilitate histamine stabilization and regulated release upon cellular activation.[5] In contrast, although several other myeloid and lymphoid cell populations—including hematopoietic progenitor cells, macrophages, neutrophils, platelets, and dendritic cells—have been shown to express HDC and generate histamine, these cells do not store histamine; instead, they release it immediately after synthesis.[6]

Following its release, the vast majority of histamine (>97%) is rapidly metabolized through 2 principal enzymatic pathways—histamine N-methyltransferase (HNMT), which accounts for approximately 50% to 80% of histamine degradation, and diamine oxidase (DAO), responsible for approximately 15% to 30% of histamine metabolism. Only a small fraction (2%-3%) of histamine is excreted unchanged.[1] HNMT is highly expressed in airway epithelial cells, underscoring its key role in histamine degradation in the airways. Pharmacological inhibition of HNMT has been shown to exacerbate histamine-induced bronchoconstriction both in vitro and in vivo, highlighting its protective role in respiratory physiology.[7] In addition to the airways, HNMT is expressed in the central nervous system and intestinal smooth muscle, and it is active alongside DAO in the small intestinal mucosa, liver, and kidneys. DAO is also found in peripheral tissues, including the placenta, skin, and eosinophils, where it serves as a key regulator of extracellular histamine levels.

Cellular Level

The biological effects of histamine are mediated through 4 distinct histamine receptor subtypes—H1, H2, H3, and H4. All histamine receptors belong to the G protein–coupled receptor (GPCR) family and share a characteristic 7-transmembrane domain structure, enabling them to transduce extracellular histamine signals into intracellular responses.

The H1 receptor is primarily coupled to G_q/11 proteins, leading to the activation of phospholipase C. This signaling cascade results in the hydrolysis of phosphatidylinositol 4,5-bisphosphate, the generation of inositol 1,4,5-trisphosphate and diacylglycerol, the elevation of intracellular calcium levels, and the subsequent activation of protein kinase C. Through these mechanisms, H1 receptor signaling mediates many of the classic pro-inflammatory effects of histamine, including vasodilation, increased vascular permeability, smooth muscle contraction, and sensory nerve activation.[8]

The H2 receptor is coupled to G_s proteins, which stimulate adenylate cyclase, resulting in increased intracellular cyclic adenosine monophosphate (cAMP) levels and activation of protein kinase A. H2 receptor signaling plays a central role in gastric acid secretion by parietal cells and also exerts immunomodulatory effects, including suppression of specific inflammatory responses.[5]

In contrast, the H3 and H4 receptors are primarily coupled to G_i/o proteins, leading to the inhibition of adenylate cyclase and a consequent decrease in intracellular cAMP levels. The H3 receptor is predominantly expressed in the central and peripheral nervous systems, where it acts as a presynaptic autoreceptor regulating the synthesis and release of histamine and other neurotransmitters. The H4 receptor is predominantly expressed on hematopoietic cells, particularly within immune cell populations—including mast cells, eosinophils, dendritic cells, and T lymphocytes—where it plays a key role in mediating chemotaxis, cytokine release, and inflammatory responses.[9]

Function

Four biochemically distinct histamine receptor subtypes (H1, H2, H3, and H4) have been identified, all of which belong to the GPCR family. These receptors mediate the diverse physiological and pathological effects of histamine in the immune, nervous, and gastrointestinal systems.

The H1 receptor is widely expressed throughout the body, including in neurons, airway and vascular smooth muscle cells, and endothelial cells. Activation of H1 receptors is responsible for the classic manifestations of allergic and anaphylactic reactions, including pruritus, pain, vasodilation, increased vascular permeability, hypotension, flushing, tachycardia, and bronchoconstriction. H1 receptors also mediate many of the histamine-dependent processes relevant to asthma pathophysiology, including smooth muscle contraction, mucosal edema, airway inflammation, and mucus secretion.[2] Accordingly, H1 receptor antagonists are widely used in the clinical management of asthma and allergic conditions, including benign forms of allergic conjunctivitis.[10] In addition to its role in allergy and inflammation, H1 receptor signaling also contributes to the regulation of sleep-wake cycles, appetite, thermoregulation, emotional and aggressive behavior, locomotion, memory, and learning.[1]

The H2 receptor is predominantly expressed in gastric parietal cells, as well as in smooth muscle cells and cardiac tissue. The activation of H2 receptors primarily stimulates gastric acid secretion and also contributes to vasodilation, increased vascular permeability, hypotension, flushing, headache, tachycardia, and bronchoconstriction. However, the clinical relevance of H2 receptors in airway function appears limited, as their direct effects on bronchial tone are relatively modest.[11] At the molecular level, activation of H2 receptors stimulates the adenylate cyclase pathway, increasing intracellular cAMP levels.[12] H2 receptor antagonists are clinically well established for the treatment of gastric and duodenal ulcers and for preventing their recurrence.

The H3 receptor is primarily expressed in histaminergic neurons of the central nervous system, where it functions as a presynaptic autoreceptor and heteroreceptor that modulates the release of histamine and other neurotransmitters, including dopamine, serotonin, norepinephrine, and acetylcholine. The identification of the H3 receptor significantly advanced understanding of the complexity of histamine-mediated neurotransmission. In addition to its role in the central nervous system, activation of H3 receptors has been shown to inhibit sympathetic vasoconstriction in the nasal mucosa.[13] H3 receptors, therefore, appear to be key regulators of histamine release from both central neurons and peripheral mast cells.

The H4 receptor is predominantly expressed in bone marrow and peripheral hematopoietic cells and plays a vital role in immune cell differentiation and chemotaxis, particularly of myeloblasts and promyeloblasts. Although H4 receptors are also GPCRs and share structural similarities with H3 receptors, their functional roles are largely immunological. However, high levels of H4 receptor messenger RNA have also been detected in the spinal cord, suggesting additional neuromodulatory function. Due to its prominent involvement in immune cell regulation, the H4 receptor is often referred to as the immune system histamine receptor and has been implicated in the pathogenesis of inflammatory and autoimmune diseases.[14]

Through its various receptor-mediated pathways, histamine plays a critical role in immunomodulation, regulating the activity, differentiation, and cytokine production of T cells, B cells, monocytes, and dendritic cells within lymphoid organs and peripheral tissues during allergic and inflammatory responses. Notably, interferon-γ production is enhanced by histamine stimulation of Th1 cells, which express high levels of H1 receptors and relatively low levels of H2 receptors. In contrast, Th2 cells exhibit lower H1 receptor expression and higher H2 receptor expression, and histamine signaling in these cells suppresses cytokine release and Th2-mediated immune responses.[15] The variability in these receptor expression patterns underscores the complex and context-dependent role of histamine in shaping adaptive and innate immune responses.

Mechanism

In humans, the immunoregulatory effects of histamine are mediated through its binding to specific G protein–coupled histamine receptors (H1-H4). Histamine signaling is highly context-dependent, and its nature and magnitude can vary with the stage of cellular differentiation, local microenvironmental conditions, receptor expression patterns, and host-specific factors, including genetic background and co-morbidities.[15]

By selectively engaging these receptors on target cells, histamine elicits the characteristic clinical manifestations of allergic reactions. Histamine acts on vascular endothelium to induce vasodilation and increase vascular permeability, stimulates sensory nerves to produce pruritus and pain, modulates glandular secretion, and promotes the activation and recruitment of innate immune cells, including neutrophils and eosinophils.[2] In addition to its role in allergic responses, histamine exerts diverse effects on multiple physiological systems, including the regulation of gastric acid secretion and central neurotransmitter signaling pathways involving dopamine, serotonin, norepinephrine, and acetylcholine. Collectively, these actions underscore histamine's central role as a multifunctional mediator linking immune activation with vascular, neural, and inflammatory responses.

Pathophysiology

Histamine plays a central role in the pathogenesis of both autoimmune and allergic diseases and has therefore been the subject of extensive investigation. The diverse effects of histamine are mediated through differential activation of histamine receptor subtypes on immune, epithelial, and neuronal cells.

Urticaria is a common dermatologic condition characterized by pruritic wheals confined to superficial layers of the skin, and angioedema involves similar edematous reactions affecting deeper mucocutaneous tissues. Acute urticaria and angioedema are typically associated with hypersensitivity reactions to allergens such as foods, medications, latex, and other environmental triggers and result from immunoglobulin E (IgE)-mediated mast cell degranulation. In contrast, chronic urticaria and angioedema are often autoimmune in nature and occur in response to circulating IgG autoantibodies directed against the high-affinity IgE receptor FcεRIα or against IgE itself, driving histamine release from basophils and mast cells.[16][17]

Allergic rhinitis is an inflammatory disorder of the nasal mucosa caused by an exaggerated immune response to airborne allergens. This condition is characterized by symptoms such as clear rhinorrhea, nasal and palatal pruritus, and sneezing. In severe cases, the reaction may also involve adjacent mucosal tissues, including the conjunctiva and middle ear. The clinical manifestations of allergic rhinitis can be largely attributed to allergen-induced histamine release. Pruritus results from activation of H1 receptors on sensory nerve endings, whereas rhinorrhea is driven by increased mucus secretion mediated by histamine- and eicosanoid-induced stimulation of muscarinic glandular pathways. For decades, H1 receptor antagonists have been the mainstay of therapy for symptom control. More recently, second-generation antihistamines—such as loratadine, cetirizine, and fexofenadine—have become preferred due to their improved receptor selectivity, reduced central nervous system penetration, and lower risk of sedation.[18]

Atopic dermatitis is a chronic, pruritic inflammatory skin condition in which persistent scratching exacerbates skin barrier dysfunction, leading to erythema, edema, fissuring, crusting, and scaling. The acute phase of atopic dermatitis is predominantly mediated by Th2-associated cytokines, whereas the chronic phase is characterized by a shift toward Th1-driven inflammation. Considered a cutaneous manifestation of atopy, atopic dermatitis frequently precedes the development of other atopic disorders, with approximately 50% to 80% of affected children developing asthma or allergic rhinitis by 5 years of age. The complex interplay among Th1 and Th2 lymphocytes, dendritic cells, keratinocytes, and histamine signaling contributes to disease pathophysiology, underscoring the need for further investigation to fully elucidate these mechanisms.[19]

Histamine's pathophysiological roles extend beyond allergic and autoimmune conditions. Histamine has recently emerged as a critical regulator of the tumor microenvironment. Studies have demonstrated that histamine modulates interactions between tumor cells and infiltrating immune cells, facilitating multiple immune evasion mechanisms that promote malignant progression.[20] In addition, histamine plays a vital role in hematopoiesis, with both endogenous and exogenous histamine promoting cell cycle progression and proliferation of hematopoietic progenitor cells. Clinically, perturbations in histamine signaling have been linked to adverse hematologic effects; notably, agranulocytosis has been reported in association with certain H2 receptor antagonists, such as cimetidine, and H4 receptor antagonists, such as clozapine, highlighting the broader systemic impact of histamine receptor modulation.[5]

Clinical Significance

H1 receptor antihistamines have been widely used for decades to treat allergic disorders, including urticaria, allergic rhinitis, and hay fever. The sedative and anticholinergic effects associated with first-generation antihistamines, which readily cross the blood-brain barrier, prompted the development of second-generation agents with improved receptor selectivity and minimal central nervous system penetration. These newer antihistamines specifically block H1 receptor activation on sensory neurons and vascular endothelial cells, thereby alleviating the symptoms of allergic disease by reducing the associated pruritus, vasodilation, and increased vascular permeability.

The introduction of H2 receptor antagonists marked a significant advance in the management of acid-related gastrointestinal disorders and led to a substantial reduction in the incidence and recurrence of gastric and duodenal ulcers before the widespread adoption of proton pump inhibitors. By competitively inhibiting histamine binding at H2 receptors on gastric parietal cells, H2 receptor antagonists suppress gastric acid secretion. These agents have been extensively used to treat peptic ulcer disease, gastroesophageal reflux disease, and functional dyspepsia. Commonly used H2 receptor antagonists include cimetidine, ranitidine, famotidine, and nizatidine.[21] These medications are particularly useful for fast-acting relief of breakthrough symptoms, in contrast to proton pump inhibitors, which require a longer period of consistent use to achieve more profound relief.

In contrast, H3 receptor antagonists are primarily under investigation for their potential therapeutic utility in neurological and neurodegenerative disorders, given the role of H3 receptors in modulating histamine and other neurotransmitter release within the central nervous system. Meanwhile, the H4 receptor, the most recently identified histamine receptor subtype, has emerged as a promising therapeutic target in autoimmune and inflammatory diseases, given its effects on hematopoiesis and immune cell differentiation. Preclinical and early clinical studies suggest that H4 receptor antagonists may be beneficial in conditions such as allergic rhinitis, chronic pruritus, and asthma.[14]

Overall, the complex interplay between histamine receptor subtypes and their downstream signaling pathways remains an active area of biomedical research, with ongoing efforts to develop more selective and effective histamine receptor–targeted therapies across a broad spectrum of diseases.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Lieberman P. The basics of histamine biology. Ann Allergy Asthma Immunol. 2011 Feb;106(2 Suppl):S2-5. [PubMed: 21277530]

2.

Xie H, He SH. Roles of histamine and its receptors in allergic and inflammatory bowel diseases. World J Gastroenterol. 2005 May 21;11(19):2851-7. [PMC free article: PMC4305649] [PubMed: 15902718]

3.

Greaves MW, Sabroe RA. Histamine: the quintessential mediator. J Dermatol. 1996 Nov;23(11):735-40. [PubMed: 8990694]

4.

Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S127-35. [PMC free article: PMC1760721] [PubMed: 16402096]

5.

Dy M, Schneider E. Histamine-cytokine connection in immunity and hematopoiesis. Cytokine Growth Factor Rev. 2004 Oct;15(5):393-410. [PubMed: 15450254]

6.

Szeberényi JB, Pállinger E, Zsinkó M, Pós Z, Rothe G, Orsó E, Szeberényi S, Schmitz G, Falus A, László V. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. Immunol Lett. 2001 Apr 02;76(3):175-82. [PubMed: 11306145]

7.

Sekizawa K, Nakazawa H, Ohrui T, Yamauchi K, Ohkawara Y, Maeyama K, Watanabe T, Sasaki H, Takishima T. Histamine N-methyltransferase modulates histamine- and antigen-induced bronchoconstriction in guinea pigs in vivo. Am Rev Respir Dis. 1993 Jan;147(1):92-6. [PubMed: 8420439]

8.

Smit MJ, Hoffmann M, Timmerman H, Leurs R. Molecular properties and signalling pathways of the histamine H1 receptor. Clin Exp Allergy. 1999 Jul;29 Suppl 3:19-28. [PubMed: 10444208]

9.

Dimitriadou V, Rouleau A, Dam Trung Tuong M, Newlands GJ, Miller HR, Luffau G, Schwartz JC, Garbarg M. Functional relationship between mast cells and C-sensitive nerve fibres evidenced by histamine H3-receptor modulation in rat lung and spleen. Clin Sci (Lond). 1994 Aug;87(2):151-63. [PubMed: 7924160]

10.

Solomon A, Pe'er J, Levi-Schaffer F. Advances in ocular allergy: basic mechanisms, clinical patterns and new therapies. Curr Opin Allergy Clin Immunol. 2001 Oct;1(5):477-82. [PubMed: 11964730]

11.

Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest. 2001 Dec;108(12):1865-73. [PMC free article: PMC209473] [PubMed: 11748270]

12.

Bertaccini G, Coruzzi G. Extragastric H2-receptors. J Clin Gastroenterol. 1983;5 Suppl 1:57-70. [PubMed: 6140284]

13.

Varty LM, Hey JA. Histamine H3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur J Pharmacol. 2002 Oct 11;452(3):339-45. [PubMed: 12359275]

14.

Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol. 2009 May;157(1):24-33. [PMC free article: PMC2697784] [PubMed: 19309354]

15.

Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Role of Histamine in Modulating the Immune Response and Inflammation. Mediators Inflamm. 2018;2018:9524075. [PMC free article: PMC6129797] [PubMed: 30224900]

16.

Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993 Jun 03;328(22):1599-604. [PubMed: 7683772]

17.

George M, Balachandran C, Prabhu S. Chronic idiopathic urticaria: comparison of clinical features with positive autologous serum skin test. Indian J Dermatol Venereol Leprol. 2008 Mar-Apr;74(2):105-8. [PubMed: 18388365]

18.

White MV. The role of histamine in allergic diseases. J Allergy Clin Immunol. 1990 Oct;86(4 Pt 2):599-605. [PubMed: 1699987]

19.

Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014 Jan;69(1):17-27. [PubMed: 24117677]

20.

Falus A, Hegyesi H, Lázár-Molnár E, Pós Z, László V, Darvas Z. Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends Immunol. 2001 Dec;22(12):648-52. [PubMed: 11738976]

21.

Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, Church MK, Saluja R. The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. Front Immunol. 2018;9:1873. [PMC free article: PMC6099187] [PubMed: 30150993]

Disclosure: Raj Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Nader Rahimi declares no relevant financial relationships with ineligible companies.